Search research articles
Contact Us
Filters
Showing results (21-30 of 48) with videos related to
Page
of 5
Sort By:
British Journal of Clinical Pharmacology
|
November 10, 2025
A quantitative model-based approach for adavosertib dose selection in patients with uterine serous carcinoma
Shankar Lanke, Kowser Miah, Damilola Olabode, et al.
ESMO Open
|
May 12, 2020
European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis
Kyriaki Tzogani, Yang Yu, Didier Meulendijks, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
October 26, 2019
Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis
Bart A W Jacobs, Maarten J Deenen, Markus Joerger, et al.
Bioanalysis
|
April 1, 2015
Improved pharmacodynamic assay for dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells
Dick Pluim, Bart A W Jacobs, Maarten J Deenen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 27, 2018
Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers
Carin A T C Lunenburg, Linda M Henricks, Eva Dreussi, et al.
Cancer Chemotherapy and Pharmacology
|
August 22, 2016
Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines
Didier Meulendijks, Linda M Henricks, André B P van Kuilenburg, et al.
ESMO Open
|
August 28, 2020
Combinations in the first-line treatment of patients with advanced/metastatic renal cell cancer: regulatory aspects
Luca Moscetti, Paula Hennik, Bjorg Bolstad, et al.
Pharmacological Research
|
December 16, 2019
Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis
Seid Hamzic, Dominic Kummer, Tanja K Froehlich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 18, 2015
Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis
Maarten J Deenen, Didier Meulendijks, Annemieke Cats, et al.
British Journal of Clinical Pharmacology
|
July 27, 2018
Food-effect study on uracil and dihydrouracil plasma levels as marker for dihydropyrimidine dehydrogenase activity in human volunteers
Linda M Henricks, Bart A W Jacobs, Didier Meulendijks, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 48) with videos related to
Sort By:
Page
of 5
British Journal of Clinical Pharmacology
|
November 10, 2025
A quantitative model-based approach for adavosertib dose selection in patients with uterine serous carcinoma
Shankar Lanke, Kowser Miah, Damilola Olabode, et al.
ESMO Open
|
May 12, 2020
European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis
Kyriaki Tzogani, Yang Yu, Didier Meulendijks, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
October 26, 2019
Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis
Bart A W Jacobs, Maarten J Deenen, Markus Joerger, et al.
Bioanalysis
|
April 1, 2015
Improved pharmacodynamic assay for dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells
Dick Pluim, Bart A W Jacobs, Maarten J Deenen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 27, 2018
Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers
Carin A T C Lunenburg, Linda M Henricks, Eva Dreussi, et al.
Cancer Chemotherapy and Pharmacology
|
August 22, 2016
Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines
Didier Meulendijks, Linda M Henricks, André B P van Kuilenburg, et al.
ESMO Open
|
August 28, 2020
Combinations in the first-line treatment of patients with advanced/metastatic renal cell cancer: regulatory aspects
Luca Moscetti, Paula Hennik, Bjorg Bolstad, et al.
Pharmacological Research
|
December 16, 2019
Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis
Seid Hamzic, Dominic Kummer, Tanja K Froehlich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 18, 2015
Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis
Maarten J Deenen, Didier Meulendijks, Annemieke Cats, et al.
British Journal of Clinical Pharmacology
|
July 27, 2018
Food-effect study on uracil and dihydrouracil plasma levels as marker for dihydropyrimidine dehydrogenase activity in human volunteers
Linda M Henricks, Bart A W Jacobs, Didier Meulendijks, et al.
Page
of 5